Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 359 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blink Tears Clear all
Completed No phase listed Observational

Mobilization and Outcomes After Venous Closure

NCT07246902
View directory record Official record
Conditions
Venous Vascular Closure, Electrophysiology Study
Interventions
MYNX CONTROLTM VENOUS Vascular Closure Device
Device
Lead sponsor
Cordis US Corp.
Industry
Eligibility
Not listed
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Littleton, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 22, 2026, 9:05 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bowel Function After Minimally Invasive Hysterectomy

NCT04263896
View directory record Official record
Conditions
Constipation
Interventions
Polyethylene Glycol 3350
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 22, 2026, 9:05 AM EDT
Completed Phase 2 Interventional Results available

A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.

NCT00364832
View directory record Official record
Conditions
Anemia
Interventions
methoxy polyethylene glycol-epoetin beta [Mircera]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
6
States / cities
Los Angeles, California • San Jose, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 22, 2026, 9:05 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine in HIV Positive, Asymptomatic and Symptomatic Individuals

NCT00000664
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin-2, Polyethylene Glycolated, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Oct 22, 2026, 9:05 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt

NCT00442364
View directory record Official record
Conditions
Varicose Veins
Interventions
Polidocanol (1%) Microfoam (Varisolve), Endovenous Microfoam Occlusion
Drug · Procedure
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
Los Angeles, California • Durham, North Carolina • Winston-Salem, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 22, 2026, 9:05 AM EDT
Terminated Not applicable Interventional Results available

Educational-Medical-Behavioral Treatment of Fecal Incontinence

NCT01717456
View directory record Official record
Conditions
Fecal Incontinence
Interventions
Education, Fiber supplements, Laxatives or anti-diarrheals, Pelvic floor muscle exercises, Tips on how to prevent fecal incontinence, Daily diary, Protective pads or garments
Other · Dietary Supplement · Drug + 1 more
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 22, 2026, 9:05 AM EDT
Completed Phase 4 Interventional

Assessment of Safety, Quality, and Acceptance of a Bowel Preparation Using a Food Kit With Laxatives

NCT07605897
View directory record Official record
Conditions
Bowel Preparation, Efficacy, Tolerability, Safety, Colon Cancer Screening, Bowel Preparation for Colonoscopy
Interventions
Use of a standardized meal content (food-kit) the day prior to colonoscopy, Polyethylene glycol 3350 - electrolyte solution (GoLYTELY)
Other · Drug
Lead sponsor
Joseph Spataro
Federal
Eligibility
18 Years to 69 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 22, 2026, 9:05 AM EDT
Completed Phase 3 Interventional Results available

A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]

NCT00160524
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab Pegol (CDP870)
Biological
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years and older
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
47
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 22, 2026, 9:05 AM EDT
Completed Phase 2 Interventional

Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00072059
View directory record Official record
Conditions
Anemia, Lung Cancer
Interventions
methoxy polyethylene glycol epoetin beta
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 22, 2026, 9:05 AM EDT
Completed Phase 1 Interventional

Study of 18F-Fluoro-PEG6-IPQA

NCT01320059
View directory record Official record
Conditions
Lung Cancer
Interventions
18F-PEG6-IPQA, Positron emission tomography (PET)
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 22, 2026, 9:05 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Patient Satisfaction and Tear Osmolarity With the Use of Blink Tears, Blink Gel Tears and Systane Balance

NCT01589640
View directory record Official record
Conditions
Dry Eye
Interventions
Blink Tears lubricating Eye Drops, Blink Gel Tears Lubricating Eye Drops, Systane Balance Lubricant Eye Drop
Other
Lead sponsor
Ophthalmic Consultants of Connecticut
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Fairfield, Connecticut
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Oct 22, 2026, 9:05 AM EDT
Recruiting Phase 2 Interventional

IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

NCT03152058
View directory record Official record
Conditions
High Risk Pregnancy, Pregnancy Complications, Antiphospholipid Syndrome in Pregnancy, Lupus Anticoagulant Disorder
Interventions
Certolizumab Pegol
Drug
Lead sponsor
David Ware Branch
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
New York, New York • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 22, 2026, 9:05 AM EDT
Terminated Phase 3 Interventional Results available

Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease

NCT00349752
View directory record Official record
Conditions
Crohn's Disease
Interventions
certolizumab pegol 400 mg, Placebo
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
54
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 22, 2026, 9:05 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

NCT00175877
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
857 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
19
States / cities
Huntsville, Alabama • San Diego, California • Danbury, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 22, 2026, 9:05 AM EDT
Completed Not applicable Interventional Results available

Safety and Tolerability of Artificial Tears in Dry Eye Subjects

NCT00932477
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear, Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear, Glycerin and Polysorbate 80 based artificial tear
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 22, 2026, 9:05 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK).

NCT00620893
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
PEG- 400 based artificial tear, Systane
Drug
Lead sponsor
Bp Consulting, Inc
Network
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2009 · Synced Oct 22, 2026, 9:05 AM EDT
Completed Phase 4 Interventional

Examining the Effect of Ondansetron on Bowel Prep Success

NCT05439772
View directory record Official record
Conditions
Abdominal Pain, Inflammatory Bowel Diseases, Eosinophilic Gastroenteritis, Diarrhea, Hematochezia, Weight Loss
Interventions
Ondansetron
Drug
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
2 Years to 20 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 22, 2026, 9:05 AM EDT
Active, not recruiting Phase 2 Interventional

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

NCT02981628
View directory record Official record
Conditions
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma
Interventions
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Diagnostic Imaging Testing, Inotuzumab Ozogamicin, Leucovorin Calcium, Lumbar Puncture, Methotrexate, Pegaspargase, Vincristine
Drug · Procedure · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
156
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 127 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 9:05 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

NCT03117751
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma
Interventions
Prednisone, Vincristine, Daunorubicin, Pegaspargase, Erwinase®, Cyclophosphamide, Cytarabine, Mercaptopurine, Dasatinib, Methotrexate, Blinatumomab, Ruxolitinib, Bortezomib, Dexamethasone, Doxorubicin, Etoposide, Clofarabine, Vorinostat, Idarubicin, Nelarabine, Thioguanine, Asparaginase Erwinia chrysanthemi (recombinant)-rywn, Calaspargase Pegol
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 18 Years
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
7
States / cities
Palo Alto, California • San Diego, California • Peoria, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 22, 2026, 9:05 AM EDT
Completed Phase 4 Interventional Results available

Pre-operative Polyethylene Glycol 3350 for Minimally Invasive Urogynecologic Surgery

NCT06159777
View directory record Official record
Conditions
Constipation, Surgical Procedure, Unspecified, Prolapse; Female
Interventions
Polyethylene Glycol 3350
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 22, 2026, 9:05 AM EDT
Completed Phase 2 Interventional Results available

Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia

NCT00671658
View directory record Official record
Conditions
Leukemia, Acute Lymphoblastic Leukemia
Interventions
Rituximab, Cyclophosphamide (CTX), Doxorubicin, Vincristine, Dexamethasone, Methotrexate (MTX), Cytarabine, G-CSF, Mesna, Pegylated asparaginase, Pegfilgrastim, Solumedrol
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Oct 22, 2026, 9:05 AM EDT
Completed Not applicable Interventional Results available

NeoMend ProGEL™ Pleural Air Leak Sealant Post-Approval Study

NCT01394978
View directory record Official record
Conditions
Lung Cancer, Lung Tumor
Interventions
Control, ProGEL Pleural Air Leak Sealant with standard surgical closure, ProGEL Pleural Air Leak Sealant without standard surgical closure
Other · Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
18
States / cities
Birmingham, Alabama • Jacksonville, Florida • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 22, 2026, 9:05 AM EDT
Completed Not applicable Interventional Results available

Instylla HES Hypervascular Tumor Pivotal Study

NCT04523350
View directory record Official record
Conditions
Hypervascular Tumors
Interventions
Instylla HES, TAE or cTACE
Device · Other
Lead sponsor
Instylla, Inc.
Industry
Eligibility
22 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Irvine, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 22, 2026, 9:05 AM EDT
Terminated Phase 4 Interventional Results available

Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept

NCT02353780
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
TNF Antagonist (enbrel, humire, remicade, cimzia, symponi), Abatacept, Tocilizumab
Drug
Lead sponsor
Dr. Larry W. Moreland
Other
Eligibility
18 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Oct 22, 2026, 9:05 AM EDT